心血管病研究团队：致力于陈可冀院士高血压防治学术思想传承，清眩降压汤防治高血压的基础和临床系列研究。遵循陈可冀老师提出高血压弦脉及其产生机制、高血压证候演变规律和临床专方“清眩降压汤”的药效，提出本病发病核心机制——肝肾阴虚、肝阳上亢；根据早治防变的中西医结合防治策略和中医药的特点，重点在高血压初起干预，予以清热平肝、滋阴潜阳，清眩降压汤干预，防靶器官损害。主要围绕四个方向：① 陈可冀老师中西医结合防治高血压学术思想研究； ② 清眩降压汤的质控分析系列研究； ③ 清眩降压汤和精制清眩降压汤的基础和临床系列研究；④ 清眩降压汤分子组方基础和临床试验研究，进一步研究高血压发病相关的肾藏精、肝藏血、心主血脉与血压调节的关系，继承陈可冀老师中西医结合高血压防治学术思想，探索清眩降压汤的药效物质基础和作用机制。
2015年来发表SCI论文
1. Xiao F, He F, Chen H, Shan Lin , Aling Shen , Youqin Chen , Jianfeng Chu, Jun Peng. Qingxuan Jiangya Decoction（清眩降压汤） Reverses Vascular Remodeling by Inducing Vascular Smooth Muscle Cell Apoptosis in Spontaneously Hypertensive Rats.[J]. 2016, 21(8)，956-966.
2.Chen, K, Lee, M, Xu, H, Zhang, Q. Complementary/Alternative Medicine in Cardiovascular Diseases 2014. Evidence-Based Complementary and Alternative Medicine, 2015, 2015, 349-375.
3. Gao, Z, Li, S, Shang, Q, Jiao, Y, Zhou, X, Fu, C, Xu, H, Shi, D. Chen, K. .Complex Networks Approach for Analyzing the Correlation of Traditional Chinese Medicine Syndrome Evolvement and Cardiovascular Events in Patients with Stable Coronary Heart Disease. Evidence-Based Complementary and Alternative Medicine, 2015, 2015, 824-850.
4.Tan C, Lu X, Chen W, Chen S. Serum ubiquitin via CXC chemokine receptor 4 triggered cyclooxygenase-1 ubiquitination possibly involved in the pathogenesis of aspirin resistance. Clinical hemorheology and microcirculation, 2015, 61, 59-81.
5.Chen, D., Lin, S., Xu, W., Huang, M., Chu, J., Xiao, F., Lin, J. Peng, J. Qualitative and Quantitative Analysis of the Major Constituents in Shexiang Tongxin Dropping Pill by HPLC-Q-TOF-MS/MS and UPLC-QqQ-MS/MS. Molecules, 2015, 20, 18597-18619.